Nuvation Bio (NUVB) Wins FDA Fast Track Status, Is The Stock Still Undervalued?
Nuvation Bio (NUVB) stock is in focus after the U.S. FDA granted Fast Track Designation to safusidenib, the company’s oral selective IDH1 inhibitor for IDH1-mutant glioma, based on encouraging clinical trial data.
The Fast Track news comes after a strong run in Nuvation Bio’s share price, with a 90 day share price return of 40.46% and a 1 year total shareholder return of 97.95%. However, the year to date share price return is down 21.10%, which suggests recent momentum may be consolidating as investors reassess the balance between potential growth from safusidenib and the risks of clinical and regulatory execution.
Seize this momentum in oncology and compare Nuvation Bio with other high-potential biopharma stocks using our hand-picked 21 high quality undiscovered gems.After a sharp move around the Fast Track news, Nuvation Bio trades well below the range of analyst and intrinsic value estimates. Is that discount a sensible reflection of clinical risk, or a potential mispricing of future cash flows?
Most Popular Narrative: 48.4% Undervalued
Based on the most followed narrative, Nuvation Bio’s fair value of $13.11 sits well above the last close at $6.77, which places significant emphasis on the long term glioma and IBTROZI opportunity.
Advancement of safusidenib into a pivotal Phase III high grade IDH1 mutant glioma maintenance study, targeting a population underserved by existing therapies, could position the company to tap into a durable brain tumor market and add a second meaningful revenue pillar that has the potential to scale earnings beyond IBTROZI.
Want to see what sits behind that potential second revenue pillar? The narrative focuses on aggressive revenue compounding, margin improvement and a future earnings multiple that most investors would not expect.
Result: Fair Value of $13.11 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this Nuvation Bio narrative could be knocked off course if the long safusidenib trial timeline slips or if future glioma competitors prove more compelling.
Find out about the key risks to this Nuvation Bio narrative.
Next Steps
If this Nuvation Bio story sounds compelling, act while sentiment is still forming and examine the data in detail with the 2 key rewards.
Looking for more investment ideas beyond Nuvation Bio?
If you want to build on the Nuvation Bio thesis, broaden your watchlist now with focused stock ideas instead of waiting for the next headline to move the market.
- Target potential mispricing by scanning for companies that combine strong fundamentals with attractive valuations through our carefully filtered list of 52 high quality undervalued stocks.
- Strengthen your income focus by hunting for businesses with higher yields and robust payout profiles using the curated universe of 11 dividend fortresses.
- Prioritise resilience by zeroing in on companies with healthier finances using the hand picked list of solid balance sheet and fundamentals (53 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com